NOMO inhibitors, as a chemical class, are not well-defined due to the indirect nature of the inhibition mechanisms. These compounds are characterized by their ability to modulate signaling pathways that are either directly or indirectly related to the function of NOMO. Given that NOMO is thought to be associated with the nodal signaling pathway, the inhibitors listed target various components of the TGF-β superfamily signaling network, which includes nodal, activin, and BMP pathways. These pathways converge on a shared group of intracellular proteins, the SMADs, which transduce signals from the cell surface to the nucleus, regulating gene expression.
The compounds presented here are primarily kinase inhibitors that target the serine/threonine kinase receptors (ALKs) involved in the propagation of TGF-β family signals. By inhibiting these receptors, they can prevent the phosphorylation event that is necessary for the activation of SMAD proteins. Once activated, SMAD proteins form complexes that translocate to the nucleus and affect gene transcription. Therefore, by preventing SMAD activation, these inhibitors can suppress the downstream signaling events that NOMO might modulate.
Items 1 to 10 of 11 total
Display:
Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
---|---|---|---|---|---|---|
SB 431542 | 301836-41-9 | sc-204265 sc-204265A sc-204265B | 1 mg 10 mg 25 mg | $80.00 $212.00 $408.00 | 48 | |
Inhibits ALK4, ALK5, and ALK7, which are activin-like kinase receptors involved in the TGF-β signaling pathway, potentially reducing the activity of NOMO by preventing activation of SMAD2/3 proteins. | ||||||
LY 364947 | 396129-53-6 | sc-203122 sc-203122A | 5 mg 10 mg | $105.00 $153.00 | 4 | |
Acts as an ATP-competitive inhibitor of the TGF-β type I receptor ALK5, potentially reducing the signaling cascade that NOMO may modulate. | ||||||
A 83-01 | 909910-43-6 | sc-203791 sc-203791A | 10 mg 50 mg | $198.00 $650.00 | 16 | |
Selectively inhibits ALK4, ALK5, and ALK7, which could reduce SMAD phosphorylation and subsequent signaling effects influenced by NOMO. | ||||||
SB-505124 | 694433-59-5 | sc-362794 sc-362794A | 10 mg 50 mg | $321.00 $1350.00 | 2 | |
An ALK5 inhibitor that could prevent the phosphorylation of SMAD proteins, potentially diminishing NOMO-related signaling. | ||||||
4-(6-(4-(Piperazin-1-yl)phenyl)pyrazolo[1,5-a]pyrimidin-3-yl)quinoline | 1062368-24-4 | sc-476297 | 5 mg | $240.00 | ||
BMP receptor inhibitor that could affect NOMO activity by modulating the BMP pathway, which interacts with nodal signaling. | ||||||
TGF-β RI Kinase Inhibitor V | 627536-09-8 | sc-203294 | 2 mg | $86.00 | 3 | |
TGF-β receptor I kinase inhibitor that could reduce SMAD2/3 phosphorylation and inhibit the signal transduction processes in which NOMO is involved. | ||||||
GW788388 | 452342-67-5 | sc-363544 sc-363544A | 5 mg 25 mg | $95.00 $384.00 | ||
Inhibits both ALK5 and ALK4, possibly impacting SMAD2/3 phosphorylation and downstream signaling that could involve NOMO. | ||||||
LY2157299 | 700874-72-2 | sc-391123 sc-391123A | 5 mg 10 mg | $209.00 $352.00 | 3 | |
Selectively inhibits the TGF-β receptor I kinase ALK5, potentially affecting NOMO activity by altering the downstream signaling pathway. | ||||||
DMH-1 | 1206711-16-1 | sc-361171 sc-361171B sc-361171A sc-361171C | 10 mg 25 mg 50 mg 100 mg | $209.00 $312.00 $620.00 $1026.00 | 2 | |
Selective inhibitor of ALK2 and ALK3, which might affect nodal signaling and thereby the function of NOMO. | ||||||
ALK5 Inhibitor II | 446859-33-2 | sc-221234 sc-221234A sc-221234B sc-221234C sc-221234D sc-221234E sc-221234F | 1 mg 5 mg 10 mg 50 mg 100 mg 500 mg 1 g | $75.00 $150.00 $215.00 $650.00 $1224.00 $4296.00 $7818.00 | 8 | |
Inhibits TGF-β receptors ALK5, ALK4, and ALK7, which could suppress SMAD phosphorylation and NOMO-related signaling. |